We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





COVID-19 Vaccine Could Give Immunity for At Least 12 Months, Says AstraZeneca

By HospiMedica International staff writers
Posted on 04 Aug 2020
The COVID-19 vaccine could give immunity from the coronavirus for at least 12 months or even provide two years of protection, according to the chief behind AstraZeneca’s (Cambridgeshire, England) trial.

Sir Mene Pangalos, the head of BioPharmaceuticals Research and Development told BBC Newscast that based on their studies, the scientists were hopeful that the immune response of the COVID-19 vaccine would last for at least 12 months but could stretch to 24 months or longer. More...
Their studies indicate that the most effective method of getting the correct dose in order to build up an immune response appears to be receiving two shots with a gap of weeks between each one. An ideal COVID-19 vaccine is expected to provide protection from the coronavirus for a minimum of six months, as well as reduce the onward transmission of the coronavirus to contacts.

WHO chief scientist Soumya Swaminathan had recently stated that AstraZeneca’s experimental COVID-19 vaccine developed by researchers at University of Oxford was possibly the world’s leading candidate and the most advanced in terms of development. Researchers believe that an ideal COVID-19 vaccine should prove effective after one or two vaccinations and work in target populations, including older adults and those with other health conditions. AstraZeneca had already commenced large-scale, mid-stage human trials of the vaccine and human clinical studies will begin in September, followed by a Phase 3 study in December 2020.

"You get your flu shot every year, hopefully it'll last longer than that but we don't know, but we'd want it to last at least 12 months, Pangalos told BBC Newscast. "But given how contagious this virus is and how much it spreads around the world I think anything that can protect you from the disease, from becoming sick, from going into hospital, I think will be a big step forward for the world."

Related Links:
AstraZeneca


New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.